Vanguard Capital Management
AXSM icon

Vanguard Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Vanguard Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$370M Buy
2,007,061
+41,975
+2% +$9.13M 0.01% 793
2026
Q2 		$481M Buy
1,965,086
+27,334
+1% +$5.93M 0.01% 724
2026
Q1 		$328M Buy
+1,937,752
New +$335M 0.01% 814

Other funds holding AXSM

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Alethea Capital Management
Alethea Capital Management Mercer Island, Washington $197M AUM 51.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Vanguard Capital Management's AXSM Position: Q3 2026 in Review

Vanguard Capital Management increased its Axsome Therapeutics (AXSM) stake by 2.1% in Q3 2026, buying an estimated $9.13M and bringing the position to 2,007,061 shares worth $370M. The position accounts for 0.01% of the portfolio, ranked #793.

Vanguard Capital Management first reported a position in AXSM in Q1 2026 and has held it in 3 quarters since. The position peaked at $481M in Q2 2026. 348 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Vanguard Capital Management held 2,007,061 shares of Axsome Therapeutics worth $370M as of Q3 2026.
  • Vanguard Capital Management bought 41,975 Axsome Therapeutics shares in Q3 2026, an estimated $9.13M.
  • Axsome Therapeutics made up 0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #793 holding.
  • Vanguard Capital Management first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Axsome Therapeutics position peaked at $481M in Q2 2026.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.